Cetuximab, a monoclonal antibody against EGFR, was found to inhibit or arrest cell cycle growth of tumor cell lines in vitro and has been tested for use as targeted therapy in cSCC, with favorable side-effect profiles [60,61]. Here, EGFR is linked to skin squamous cell carcinoma.